HomeCeloNova Biosciences

CeloNova Biosciences

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

5/24/18: "The data from this trial provides further evidence that COBRA PzF NCS is a safe and effective treatment, particularly in complex patients with heart disease," said Luc Maillard, MD, principal investigator for the eCOBRA trial and Director of the Department of Cardiology, Clinique Axium, Aix-en-Provence, France. “Being able to provide an effective therapy that meets the needs of patients who are at higher risk of bleeding is of great clinical value.”

FDA Approves NanoCoated Coronary Stent System Using DSG’s eClinical Systems

CeloNova Biosciences, Inc., leveraging products and services provided by DSG, Inc., a leading eClinical software technology and data management global services firm, recently received US Food and Drug Administration (FDA) approval of its first-in-class COBRA PzF™ NanoCoated...